Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 2/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.56 |
| ▸ | DHFR | P00374 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3538359 | 0.99 | SLC6A9 (0.60) | SLC6A9SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL3538639 | 0.96 | SLC6A9 (0.56) | SLC6A9SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL3536275 | 0.83 | GPR88 (0.57) | SLC6A9SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL1795282 | 0.81 | SLC6A9 (0.76) | SLC6A9SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL1795284 | 0.81 | SLC6A9 (0.76) | SLC6A9SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL26840798 | 0.79 | SLC6A9 (0.73) | SLC6A9SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL3289063 | 0.78 | SLC6A3 (0.48) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL4589243 | 0.77 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL4589246 | 0.77 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL6919211 | 0.77 | SLC6A9 (0.59) | SLC6A9SLC6A3SLC6A2SLC6A4DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951821-B2 | Devoided of activity on the opiate or 5-HT3 receptors, exhibit a particular activity as specific inhibitors of the glycine transporters glyt1 and/or glyt2; 2-Chloro-N-[(S)-phenyl-[(2S)-piperidin-2-yl]methyl]-3-(trifluoromethyl)benzamide | SANOFI-AVENTIS (FR) | 2011-05-31 | — | — | US | disclosed |
| US-7951821-B2 | Devoided of activity on the opiate or 5-HT3 receptors, exhibit a particular activity as specific inhibitors of the glycine transporters glyt1 and/or glyt2; 2-Chloro-N-[(S)-phenyl-[(2S)-piperidin-2-yl]methyl]-3-(trifluoromethyl)benzamide | SANOFI-AVENTIS (FR) | 2011-05-31 | — | — | US | disclosed |
| US-7947675-B2 | N-(3,4-dichlorophenyl)-3-nitro-2-piperid-1-yl-5-trifluoromethylbenzamide; repressors of cholesterol ester transfer protein, CETP; decreases low-density lipoproteins and triglycerides in blood plasma; cardiovascular diseases, atherosclerosis, dyslipidaemia and type II diabetes, obesity, nephropathy | MERCK PATENT GMBH (DE) | 2011-05-24 | — | — | US | disclosed |
| CN-100482646-C | N- [ phenyl (piperidin-2-yl) methyl ] benzamide derivatives, their preparation and their use in therapy | SANOFI AVENTIS (FR) | 2009-04-29 | — | — | CN | disclosed |
| EP-1858867-B1 | TRIFLUOROMETHYLBENZAMIDE DERIVATIVES AND THERAPEUTIC USES THEREOF | MERCK PATENT GMBH (DE) | 2009-01-07 | — | — | EP | disclosed |
| US-20080119459-A1 | Trifluoromethylbenzamide Derivatives and Therapeutic Uses Thereof | MERCK PATENT GMBH (DE) | 2008-05-22 | — | — | US | disclosed |
| US-7326722-B2 | N-[Phenyl(piperidin-2-yl)methyl]benzamide derivatives, their preparation and their application in therapy | SANOFI-AVENTIS (FR) | 2008-02-05 | — | — | US | disclosed |
| EP-1858867-A1 | TRIFLUOROMETHYLBENZAMIDE DERIVATIVES AND THERAPEUTIC USES THEREOF | Merck Patent GmbH (DE) | 2007-11-28 | — | — | EP | disclosed |
| US-20070197601-A1 | Use of N-[Phenyl(piperidin-2-yl)methyl]benzamide derivatives in therapy | SANOFI-AVENTIS (FR) | 2007-08-23 | — | — | US | disclosed |
| US-20070155789-A1 | N-[PHENYL(PIPERIDIN-2-YL)METHYL]BENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN THERAPY | SANOFI-AVENTIS (FR) | 2007-07-05 | — | — | US | disclosed |
| US-7205319-B2 | exhibit a particular activity as specific inhibitors of the glycine transporters glyt1 and/or glyt2 | SANOFI-AVENTIS (FR) | 2007-04-17 | — | — | US | disclosed |
| CN-1882540-A | N- [ phenyl (piperidin-2-yl) methyl ] benzamide derivatives, their preparation and their therapeutic use | SANOFI AVENTIS (FR) | 2006-12-20 | — | — | CN | disclosed |
| WO-2006097169-A1 | TRIFLUOROMETHYLBENZAMIDE DERIVATIVES AND THERAPEUTIC USES THEREOF | MERCK PATENT GMBH (DE) | 2006-09-21 | — | — | WO | disclosed |
| CN-1662497-A | N- [ phenyl (piperidin-2-yl) methyl ] benzamide derivatives, their preparation and their use in therapy | SANOFI AVENTIS (FR) | 2005-08-31 | — | — | CN | disclosed |
| US-20050159450-A1 | Derivative of n-[phenyl(piperidin-2-yl)methyl]benzamide, the preparation method thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2005-07-21 | — | — | US | disclosed |
| US-20050153963-A1 | N-[phenyl (piperidin-2-yl) methyl]benzamide derivatives, preparation thereof, and use thereof in therapy | SANOFI-AVENTIS (FR) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197601-A1 | Use of N-[Phenyl(piperidin-2-yl)methyl]benzamide derivatives in therapy | SLC1A2, SLC1A1, SLC1A5 | SLC6A9 53/4885SLC6A3 158/4885SLC6A2 82/4885 |
| US-20050153963-A1 | N-[phenyl (piperidin-2-yl) methyl]benzamide derivatives, preparation thereof, and use thereof in therapy | HDAC6, NAT1, ARG2 | SLC6A9 3416/4885SLC6A3 1390/4885SLC6A2 1222/4885 |
| US-20050159450-A1 | Derivative of n-[phenyl(piperidin-2-yl)methyl]benzamide, the preparation method thereof and application of same in therapeutics | NPR3, NR4A3, PRMT3 | SLC6A9 4691/4885SLC6A3 1031/4885SLC6A2 2090/4885 |
| US-20080119459-A1 | Trifluoromethylbenzamide Derivatives and Therapeutic Uses Thereof | REN, ADRB3, CYP11B2 | SLC6A9 4466/4885SLC6A3 3120/4885SLC6A2 2979/4885 |
| US-20070155789-A1 | N-[PHENYL(PIPERIDIN-2-YL)METHYL]BENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN THERAPY | HDAC6, NAT1, ARG2 | SLC6A9 3416/4885SLC6A3 1390/4885SLC6A2 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.